BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20575024)

  • 61. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
    Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genes and chromosomes in chronic B-cell leukemia.
    Crossen PE
    Cancer Genet Cytogenet; 1997 Mar; 94(1):44-51. PubMed ID: 9078290
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.
    Wlodarska I; Dierickx D; Vanhentenrijk V; Van Roosbroeck K; Pospísilová H; Minnei F; Verhoef G; Thomas J; Vandenberghe P; De Wolf-Peeters C
    Blood; 2008 Jun; 111(12):5683-90. PubMed ID: 18391076
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Weighted gene co-expression network analysis in identification of endometrial cancer prognosis markers.
    Zhu XL; Ai ZH; Wang J; Xu YL; Teng YC
    Asian Pac J Cancer Prev; 2012; 13(9):4607-11. PubMed ID: 23167388
    [TBL] [Abstract][Full Text] [Related]  

  • 65. p53 is a direct transcriptional target of MYCN in neuroblastoma.
    Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA
    Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
    Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
    Moshynska O; Sankaran K; Pahwa P; Saxena A
    J Natl Cancer Inst; 2004 May; 96(9):673-82. PubMed ID: 15126604
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Isolation of a novel candidate proto-oncogene involved in human lymphoid neoplasm].
    Ohno H
    Rinsho Ketsueki; 1991 Jun; 32(6):655-9. PubMed ID: 1890743
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rearrangement and expression of MDM2 oncogene in chronic lymphocytic leukemia.
    Huang YQ; Raphael B; Buchbinder A; Li JJ; Zhang WG; Friedman-Kien AE
    Am J Hematol; 1994 Oct; 47(2):139-41. PubMed ID: 8092130
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
    Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
    Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cancer biology. A new cancer player takes the stage.
    Couzin J
    Science; 2005 Nov; 310(5749):766-7. PubMed ID: 16272095
    [No Abstract]   [Full Text] [Related]  

  • 72. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia.
    Kostopoulou F; Gabillaud C; Chapiro E; Grange B; Tran J; Bouzy S; Degaud M; Ghamlouch H; Le Garff-Tavernier M; Maloum K; Choquet S; Leblond V; Gabarre J; Lavaud A; Morel V; Roos-Weil D; Uzunov M; Guieze R; Bernard OA; Susin SA; Tournilhac O; Nguyen-Khac F;
    Cancer Med; 2019 Jun; 8(6):3131-3141. PubMed ID: 31066214
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regulation of the turnover of mRNAs encoding cellular oncoproteins.
    Saini KS; Summerhayes IC
    Biochem Cell Biol; 1991 Jul; 69(7):415-7. PubMed ID: 1838927
    [No Abstract]   [Full Text] [Related]  

  • 75. A patient with de novo 0.45 Mb deletion of 2p16.1: the role of BCL11A, PAPOLG, REL, and FLJ16341 in the 2p15-p16.1 microdeletion syndrome.
    Hancarova M; Simandlova M; Drabova J; Mannik K; Kurg A; Sedlacek Z
    Am J Med Genet A; 2013 Apr; 161A(4):865-70. PubMed ID: 23495096
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
    Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
    Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion.
    Becker J; Volland S; Noskova I; Schramm A; Schweigerer LL; Wilting J
    Int J Oncol; 2008 Jan; 32(1):235-40. PubMed ID: 18097563
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pleiotropic role for MYCN in medulloblastoma.
    Swartling FJ; Grimmer MR; Hackett CS; Northcott PA; Fan QW; Goldenberg DD; Lau J; Masic S; Nguyen K; Yakovenko S; Zhe XN; Gilmer HC; Collins R; Nagaoka M; Phillips JJ; Jenkins RB; Tihan T; Vandenberg SR; James CD; Tanaka K; Taylor MD; Weiss WA; Chesler L
    Genes Dev; 2010 May; 24(10):1059-72. PubMed ID: 20478998
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus.
    Dyer MJ; Lillington DM; Bastard C; Tilly H; Lens D; Heward JM; Stranks G; Morilla R; Monrad S; Guglielmi P; Kluin-Nelemans JC; Hagemeijer A; Young BD; Catovsky D
    Leukemia; 1996 Jul; 10(7):1198-208. PubMed ID: 8684002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.